Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib

Leuk Res. 2010 Aug;34(8):e215-6. doi: 10.1016/j.leukres.2010.02.037. Epub 2010 Mar 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnosis*
  • Piperazines / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases